Digest Network Come funziona
Network
/
Società
C₂
Non verificato

C₂N Diagnostics, LLC

Di cosa scriviamo

BiotecnologiaIndustriaSaluteSanitàScienza

24 comunicati stampa

Guarda tutti i comunicati
21/09/2026
Industria
Associazioni/Professionisti
Terza età
Scienza
Igiene alimentare
Sanità
Famiglia
Vetrine/Shopping
Attrezzature medico-sanitarie
Medicina - Varie
Salute
C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer's Trust to Improve Alzheimer's Disease Diagnosis
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
18/09/2026
‘Live Long and Prosper’: Nimoy-Knight Foundation Selects C2N’s CEO and Co-Founder for Prestigious Award Following Alzheimer’s Disease Blood Test FDA Clearance
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
20/08/2026
Multimedialità
Industria
Sanità
Terza età
Scienza
Farmaceutica
Psichiatria
Attrezzature medico-sanitarie
Vetrine/Shopping
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
29/07/2026
Industria
Scienza
Psichiatria
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
09/07/2026
Industria
Scienza
Sanità
Vetrine/Shopping
Medicina - Varie
Biotecnologia
Terza età
Salute
Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Sanità
Psichiatria
Salute
Industria
C2N Diagnostics and SouthGenetics Partner to Enable Broader Access to Precivity® Blood Tests for Alzheimer’s Disease Assessment in Latin America, Caribbean
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
19/03/2026
Industria
Psichiatria
Sanità
Scienza
Biotecnologia
Vetrine/Shopping
Medicina - Varie
Igiene alimentare
Salute
Farmaceutica
Terza età
C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
11/03/2026
Mercato del lavoro
Industria
Farmaceutica
Sanità
Attrezzature medico-sanitarie
Salute
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
13/11/2025
Psichiatria
Salute
Scienza
Eventi
C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0
25/09/2025
Industria
Sanità
Terza età
Medicina - Varie
Scienza
Biotecnologia
Vetrine/Shopping
Salute
New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients
Fonte
C₂N Diagnostics, LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0